ScholarIQanswers from OpenAlex & ORCID
David Cameron
ResearcherPublications, citations & collaboration network
David Cameron is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David Cameron have?
ScholarIQindexed works
David Cameron has 1,031 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David Cameron have?
ScholarIQcitation count
David Cameron has 67,192 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David Cameron?
ScholarIQh-index
David Cameron has an h-index of 108 in OpenAlex.
What is the i10-index of David Cameron?
ScholarIQi10-index
David Cameron has an i10-index of 428 in OpenAlex.
What is the ORCID of David Cameron?
ScholarIQorcid
The ORCID for David Cameron is on the source record.
What is the OpenAlex record for David Cameron?
ScholarIQopenalex
The OpenAlex for David Cameron is on the source record.
What are the most-cited papers on David Cameron?
ScholarIQmost cited works
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith, Marion Procter, Richard D. Gelber, Sébastien Guillaume, A. Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, José Baselga, Manfred Kaufmann, David Cameron, Richard H. Bell, Jonas Bergh, Robert L. Coleman, Andrew Wardley, Nadia Harbeck, R.I. Lopez, Peter Mallmann, Karen A. Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez‐Rovira, Martine Piccart